The National Health Surveillance Agency (Anvisa) reported that, on Monday, 28, a meeting was held with technicians from the agency and the Butantan Institute to discuss the Butanvac vaccine against covid-19. According to the agency, the clinical research protocol is already approved, but there is still a lack of specific data to start the tests in humans.
In a note, the regulatory body states that the purpose of the meeting was to evaluate the information already presented by Butantan. “But for the vaccine to start being applied to human beings, it is necessary to present specific data, which are still being generated by Butantan”, he says. According to Anvisa, an example of the missing data refers to the inactivation of the virus used in the vaccine.